G Gomez1, F C Stanford2,3. 1. Department of Surgery-Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 2. Weight Center, Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. 3. Department of Pediatrics-Endocrinology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Abstract
OBJECTIVE: Obesity is now the most prevalent chronic disease in the United States, which amounts to an estimated $147 billion in health care spending annually. The Affordable Care Act (ACA) enacted in 2010 included provisions for private and public health insurance plans that expanded coverage for lifestyle/behavior modification and bariatric surgery for the treatment of obesity. Pharmacotherapy, however, has not been included despite their evidence-based efficacy. We set out to investigate the coverage of Food and Drug Administration-approved medications for obesity within Medicare, Medicaid and ACA-established marketplace health insurance plans. METHODS: We examined coverage for phentermine, diethylpropion, phendimetrazine, Benzphentamine, Lorcaserin, Phentermine/Topiramate (Qysmia), Liraglutide (Saxenda) and Buproprion/Naltrexone (Contrave) among Medicare, Medicaid and marketplace insurance plans in 34 states. RESULTS: Among 136 marketplace health insurance plans, 11% had some coverage for the specified drugs in only nine states. Medicare policy strictly excludes drug therapy for obesity. Only seven state Medicaid programs have drug coverage. CONCLUSIONS: Obesity requires an integrated approach to combat its public health threat. Broader coverage of pharmacotherapy can make a significant contribution to fighting this complex and chronic disease.
OBJECTIVE:Obesity is now the most prevalent chronic disease in the United States, which amounts to an estimated $147 billion in health care spending annually. The Affordable Care Act (ACA) enacted in 2010 included provisions for private and public health insurance plans that expanded coverage for lifestyle/behavior modification and bariatric surgery for the treatment of obesity. Pharmacotherapy, however, has not been included despite their evidence-based efficacy. We set out to investigate the coverage of Food and Drug Administration-approved medications for obesity within Medicare, Medicaid and ACA-established marketplace health insurance plans. METHODS: We examined coverage for phentermine, diethylpropion, phendimetrazine, Benzphentamine, Lorcaserin, Phentermine/Topiramate (Qysmia), Liraglutide (Saxenda) and Buproprion/Naltrexone (Contrave) among Medicare, Medicaid and marketplace insurance plans in 34 states. RESULTS: Among 136 marketplace health insurance plans, 11% had some coverage for the specified drugs in only nine states. Medicare policy strictly excludes drug therapy for obesity. Only seven state Medicaid programs have drug coverage. CONCLUSIONS:Obesity requires an integrated approach to combat its public health threat. Broader coverage of pharmacotherapy can make a significant contribution to fighting this complex and chronic disease.
Authors: William H Dietz; Loel S Solomon; Nico Pronk; Sarah K Ziegenhorn; Marion Standish; Matt M Longjohn; David D Fukuzawa; Ihuoma U Eneli; Lisel Loy; Natalie D Muth; Eduardo J Sanchez; Jenny Bogard; Don W Bradley Journal: Health Aff (Millwood) Date: 2015-09 Impact factor: 6.301
Authors: Anita P Courcoulas; Steven H Belle; Rebecca H Neiberg; Sheila K Pierson; Jessie K Eagleton; Melissa A Kalarchian; James P DeLany; Wei Lang; John M Jakicic Journal: JAMA Surg Date: 2015-10 Impact factor: 14.766
Authors: Caroline M Apovian; Louis J Aronne; Daniel H Bessesen; Marie E McDonnell; M Hassan Murad; Uberto Pagotto; Donna H Ryan; Christopher D Still Journal: J Clin Endocrinol Metab Date: 2015-01-15 Impact factor: 5.958
Authors: Elizabeth G Mietlicki-Baase; Claudia G Liberini; Jayme L Workinger; Ron L Bonaccorso; Tito Borner; David J Reiner; Kieran Koch-Laskowski; Lauren E McGrath; Rinzin Lhamo; Lauren M Stein; Bart C De Jonghe; George G Holz; Christian L Roth; Robert P Doyle; Matthew R Hayes Journal: Diabetes Obes Metab Date: 2018-02-20 Impact factor: 6.577
Authors: Mina Kabiri; Alison Sexton Ward; Abhilasha Ramasamy; Rebecca Kee; Rahul Ganguly; Brian Gabriel Smolarz; Tracy Zvenyach; James R Baumgardner; Dana P Goldman Journal: Inquiry Date: 2021 Jan-Dec Impact factor: 1.730